The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Real world outcome for high-risk NDMM
Andrew Spencer, MBBS, FRACP FRCPA, DM, Alfred Health-Monash University, Melbourne, Australia, discusses real world data on the outcome for newly diagnosed patients with functional high-risk (HR) multiple myeloma (MM). Prof. Spencer explains how one of the frustrations in treating myeloma is the lack of a uniformly recognized risk-stratification model that not only recognizes HR disease, but is also accessible and affordable. In order to overcome this limitation and enable the appropriate therapeutic targeting of HR patients, data from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) were evaluated, with the aim of identifying characteristics of functional HR disease that could inform response-adaptive strategies. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
